Kwang Dong Pharmaceutical Co., Ltd.

KOSE:A009290 Stock Report

Market Cap: ₩218.0b

Kwang Dong Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Kwang Dong Pharmaceutical has been growing earnings at an average annual rate of 3.8%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 6.2% per year. Kwang Dong Pharmaceutical's return on equity is 5.7%, and it has net margins of 2.1%.

Key information

3.8%

Earnings growth rate

3.6%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate6.2%
Return on equity5.7%
Net Margin2.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Kwang Dong Pharmaceutical's (KRX:009290) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 24
Kwang Dong Pharmaceutical's (KRX:009290) Weak Earnings May Only Reveal A Part Of The Whole Picture

Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Mar 25
Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

Dec 04
Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

Recent updates

Kwang Dong Pharmaceutical's (KRX:009290) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 24
Kwang Dong Pharmaceutical's (KRX:009290) Weak Earnings May Only Reveal A Part Of The Whole Picture

There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding

Aug 06
There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding

Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Mar 25
Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking

Mar 20
Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking

Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?

Apr 29
Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?

Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?

Apr 06
Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?

Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?

Mar 18
Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?

Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?

Mar 01
Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?

Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?

Feb 14
Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?

Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)

Feb 01
Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)

Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly

Jan 19
Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly

If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late

Jan 06
If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late

Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend

Dec 24
Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend

Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?

Dec 18
Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?

Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

Dec 04
Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?

Nov 21
What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?

Revenue & Expenses Breakdown

How Kwang Dong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A009290 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,634,19833,873248,06514,198
30 Jun 241,607,44433,887244,96813,942
31 Mar 241,569,99141,121240,26213,816
31 Dec 231,514,45436,966233,84815,275
30 Sep 231,509,98138,578232,56611,458
30 Jun 231,489,79336,189232,63811,757
31 Mar 231,476,24830,631228,27011,346
31 Dec 221,431,54524,174225,6469,678
30 Sep 221,412,47823,615222,6689,416
30 Jun 221,385,26426,115214,2829,013
31 Mar 221,356,28725,453212,9868,383
31 Dec 211,338,18224,019212,9618,322
30 Sep 211,282,05610,642205,5526,955
30 Jun 211,247,49632,216201,9936,401
31 Mar 211,237,24040,840197,8406,855
31 Dec 201,243,77045,370195,6785,957
30 Sep 201,256,38854,621200,9635,704
30 Jun 201,244,06428,203203,1725,830
31 Mar 201,244,96324,627201,9865,164
31 Dec 191,238,25523,058199,9165,339
30 Sep 191,215,66722,304193,4175,967
30 Jun 191,224,38626,756189,9145,186
31 Mar 191,198,93924,200192,2694,919
31 Dec 181,180,22022,345192,9674,179
30 Sep 181,163,67323,471192,4903,200
30 Jun 181,148,40225,169194,4263,221
31 Mar 181,152,53324,153199,7242,307
31 Dec 171,141,56623,196200,5151,513
30 Sep 171,128,69322,482203,338858
30 Jun 171,100,13720,602204,2980
31 Mar 171,076,30626,392199,4170
31 Dec 161,056,42928,063194,6470
30 Sep 161,066,94431,922190,3800
30 Jun 161,076,68133,587187,1100
31 Mar 161,077,61735,062180,1960
31 Dec 15955,45435,015174,1830
30 Sep 15808,36336,695163,7770
30 Jun 15674,91337,955151,7270
31 Mar 15533,99936,215142,4530
31 Dec 14522,27435,044137,4620
30 Sep 14508,92332,721133,3580
30 Jun 14497,11131,688130,1180
31 Mar 14479,96523,047123,9060
31 Dec 13468,38522,037120,3280

Quality Earnings: A009290 has a large one-off gain of ₩27.8B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A009290's current net profit margins (2.1%) are lower than last year (2.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A009290's earnings have grown by 3.8% per year over the past 5 years.

Accelerating Growth: A009290's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A009290 had negative earnings growth (-12.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22.3%).

Return on Equity

High ROE: A009290's Return on Equity (5.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 12:14
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kwang Dong Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tae Gi HaSK Securities Co., Ltd.
Jayaprabha DhavaleVirtua Research Inc.